Transaction DateRecipientSharesTypePriceValue
18th February 2021Thomas John Dietz9,000Grant/award etc.$0.00
10th February 2021Amit Sachdev2,421Payment by withholding$214.16$518,481.36
3rd February 2021Amit Sachdev10,324Grant/award etc.$0.00
3rd February 2021Amit Sachdev10,126Grant/award etc.$0.00
3rd February 2021Amit Sachdev11,627Grant/award etc.$0.00
8th January 2021Eldon C. Iii Mayer1,690Open or private sale$11.68$19,739.20
8th December 2020Amit Sachdev3,391Bona fide gift$0.00
13th November 2020Evan Loh20,928Open or private sale$5.93$124,103.04
12th November 2020Evan Loh75,000Grant/award etc.$0.00
29th October 2020Evan Loh39,479Exercise of derivative$4.30$169,759.70
Eiger Bio Pharmaceuticals
Eiger Bio Pharmaceuticals logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.

Eiger BioPharmaceuticals, Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of well-characterized drugs for life-threatening, rare and ultra-rare diseases.

Ticker: EIGR
Sector: Healthcare
Industry: Biotechnology
SEC Central Index Key (CIK): 1305253
Employees: 18
Exchange: NASDAQ
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $63 M (0%)
Assets, Current: $97 M (-3%)
Property, Plant and Equipment, Net: $616 Th (4%)
Other Assets, Noncurrent: $4 M (50%)
Assets: $103 M (-1%)
Long-term Debt, Current Maturities: $3 M (0%)
Accounts Payable, Current: $5 M (-19%)
Accrued Liabilities, Current: $7 M (0%)
Liabilities, Current: $16 M (-4%)
Long-term Debt, Excluding Current Maturities: $27 M (0%)
Liabilities: $45 M (-8%)
Common Stock, Value, Issued: $27 Th (12%)
Additional Paid in Capital, Common Stock: $330 M (10%)
Retained Earnings (Accumulated Deficit): $272 M (0%)
Accumulated Other Comprehensive Income (Loss), Net of Tax: $45 Th (7%)
Stockholders' Equity (Parent): $58 M (0%)
Liabilities and Equity: $103 M (-1%)
Research and Development: $10 M (-49%)
General and Administrative Expenses: $5 M (-51%)
Operating Income/Loss: $15 M (-50%)